BioAtla, Inc. Profile Avatar - Palmy Investing

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conj…

Biotechnology
US, San Diego [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of BCAB's Analysis
CIK: 1826892 CUSIP: 09077B104 ISIN: US09077B1044 LEI: - UEI: -
Secondary Listings
BCAB has no secondary listings inside our databases.